PHRM 211 Lecture Notes - Lecture 25: Catabolism, Choline Acetyltransferase, Nonsteroidal Anti-Inflammatory Drug
Document Summary
Pathophysiology & pharmacology of dementia (part 2) A substance, measurement or indicator of a biological state. Should detect a fundamental feature of the molecular pathogenesis or neuropathology of ad. Should be validated in neuropathologically confirmed ad cases. Should have a sensitivity >80% for detecting ad and a specificity >80% for differentiating ad from other dementias. Should be able to detect ad in its early stages (i. e. during mci) Be reliable, reproducible, noninvasive, simple to perform, inexpensive and, thus, adaptable in routine clinical practice. Common biomarkers for ad (related to different spheres of detection) Compare and contrast the major hypotheses that contribute to ad. The cholinergic system is involved in memory function. Cholinergic deficiency has been implicated in the cognitive decline and behavioral changes of ad. In ad, choline acetyltransferase (cat) and the catabolic enzyme acetylcholinesterase are significantly decreased in the cerebral cortex, hippocampus, and amygdala.
